MDT (multi-disciplinary team) guidance for managing prostate cancer

Side-effects
• A review of 16 studies by Crook et al. showed acute adverse events as: 67
o Irritant urinary symptoms: 46−54%
o Acute urinary retention: 1−14%
o Acute proctitis: 1−2%
o Chronic adverse events (reinforced by Wills et al., 1999 71 ):
• Incontinence: 5−6%
• Haematuria: 1−2%
• Strictures: 1−2%
• Proctitis: 1−3%
• Erectile dysfunction: 4−14% (or up to 38% in Wills et al., 1999 71 and up to 50% at 5 years
in Merrick et al., 2001 68 ).
Clinical evidence
Table 4: Experience using trans-perineal implants as monotherapy (T1, T2 cancers)
Author Number of men Isotope
*Series excluded Gleason grade >7, 38% with pre-treatment PSA ≤4.0 ng/ml
Median follow-up PSA results
(months) (months)
Beyer & Priestley,
79% with PSA
489 I-125 35
199772